Pharma-Bio Serv, Inc. (PBSV)
OTCMKTS · Delayed Price · Currency is USD
0.590
+0.100 (20.41%)
Mar 6, 2026, 4:00 PM EST

Pharma-Bio Serv Ratios and Metrics

Millions USD. Fiscal year is Nov - Oct.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Mar '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21 2020 - 2016
Market Capitalization
111213202024
Upgrade
Market Cap Growth
-41.89%-7.06%-31.76%-1.11%-16.81%-20.06%
Upgrade
Enterprise Value
021568
Upgrade
Last Close Price
0.490.470.440.600.570.58
Upgrade
PE Ratio
---14.8919.60-
Upgrade
Forward PE
4.45208.00208.00208.00208.00208.00
Upgrade
PS Ratio
1.251.381.401.151.021.18
Upgrade
PB Ratio
0.941.040.971.211.191.25
Upgrade
P/TBV Ratio
0.941.040.971.211.191.25
Upgrade
P/FCF Ratio
---10.3634.4229.87
Upgrade
P/OCF Ratio
---10.3233.3129.47
Upgrade
PEG Ratio
-14.8614.8614.8614.8614.86
Upgrade
EV/Sales Ratio
0.040.190.070.310.310.39
Upgrade
EV/EBITDA Ratio
---4.564.91-
Upgrade
EV/EBIT Ratio
---4.755.12-
Upgrade
EV/FCF Ratio
-1.79--2.8210.499.97
Upgrade
Debt / Equity Ratio
0.000.000.010.020.030.03
Upgrade
Debt / EBITDA Ratio
---0.260.35-
Upgrade
Debt / FCF Ratio
---0.180.850.78
Upgrade
Net Debt / Equity Ratio
-0.91-0.91-0.91-0.91-0.84-0.89
Upgrade
Net Debt / EBITDA Ratio
18.7418.749.93-12.55-11.404.46
Upgrade
Net Debt / FCF Ratio
48.8748.8717.28-7.77-24.38-21.22
Upgrade
Asset Turnover
0.600.600.530.840.870.75
Upgrade
Quick Ratio
7.607.608.088.789.238.27
Upgrade
Current Ratio
7.707.708.329.019.468.55
Upgrade
Return on Equity (ROE)
-0.78%-0.78%-5.21%8.02%5.68%-10.04%
Upgrade
Return on Assets (ROA)
-2.66%-2.66%-4.45%3.44%3.29%-8.95%
Upgrade
Return on Invested Capital (ROIC)
-54.01%-56.62%-96.81%42.55%42.85%-74.35%
Upgrade
Return on Capital Employed (ROCE)
-5.40%-5.40%-8.90%6.30%6.30%-18.10%
Upgrade
Earnings Yield
-0.90%-0.81%-5.84%6.71%5.10%-8.81%
Upgrade
FCF Yield
-1.97%-1.79%-5.46%9.65%2.90%3.35%
Upgrade
Payout Ratio
---131.57%342.37%-
Upgrade
Buyback Yield / Dilution
0.07%0.07%0.10%0.15%0.56%-0.53%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.